Carnitine Supplementation in Type 2 Diabetic Patients

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

November 11, 2019

Study Completion Date

November 11, 2019

Conditions
Glucose Intolerance
Interventions
DRUG

Carnitene (L-Carnitine or Levocarnitine)

All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.

Trial Locations (1)

6229ER

Maastricht University, Maastricht

All Listed Sponsors
lead

Maastricht University Medical Center

OTHER

NCT03230812 - Carnitine Supplementation in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter